
Safety of tiotropium in patients with asthma



Proportion of patients reporting AEs is balanced and similar with tiotropium and placebo, irrespective of several baseline characteristics, including age, disease severity, gender and across ethnic groups



Spiriva Respimat[®] is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. SPIRIVA[®] Respimat[®] Summary of Product Characteristics. Boehringer Ingelheim GmbH. October 2018. Available **here**.